Luke Lapointe

Luke Lapointe inquired about the remaining estimated 90% untreated prevalent market for CRENESSITY, asking for the proportion managed by an endocrinologist versus primary care or other settings.

Answer

Chief Commercial Officer Eric Benevich stated that the company is still learning the exact proportion of patients managed by endocrinologists versus primary care or other settings. He noted observations of co-management and emphasized leveraging technology and the expanded sales team to identify and educate prescribers in practices with multiple CAH patients, including non-endocrinologists.

Luke Lapointe asked about the remaining 90% of the untreated prevalent CRENESSITY market, specifically inquiring about the proportion managed by endocrinologists versus primary care or other settings.

Answer

Eric Benevich, Chief Commercial Officer, stated that Neurocrine is still learning the exact proportion, noting that some patients appear to be co-managed by endocrinologists and primary care physicians. He emphasized the importance of teasing out this data and leveraging the expanded sales team to identify and engage primary care or OB/GYN practices with multiple CAH patients to better understand patient locations and optimize education and activation methods.

Speaking for Brian Skorney, Luke Lapointe of Baird asked if the company has set a target for the quantity of RGX-202 commercial product it expects to have available at launch.

Answer

President and CEO Curran Simpson explained that while a specific number is still under evaluation, the goal is to have a significant number of doses ready to quickly address the prevalent ambulatory market, which they estimate at 5,000-7,000 patients. He reiterated their facility can produce 2,500 doses annually, enabling them to build a substantial inventory before launch.